REBLOZYL

The mark consists of the word REBLOZYL in purple with three pink and purple dots to the right of the word.

Mark For: REBLOZYL® trademark registration is intended to cover the categories of pharmaceutical preparations for use in the treatment of anemia, beta thalassemia, myelodsplatic syndromes, autoinflammatory disease, autoimmune disease, blood disease, cancer, arthritis, musculoskeletal and skin diseases in the fields of oncology, immunology and inflammation; pharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; Pharmaceutical preparations for use in the treatment of anemia, beta thalassemia, blood disease, cancer. [all]

>The color(s) purple and pink is/are claimed as a feature of the mark. The mark consists of the word "REBLOZYL" in purple with three pink and purple dots to the right of the word.

Status

2020-03-09 UTC
⟳ Refresh

LIVE APPLICATION Awaiting Examination

Research	OneLook Acronym Finder
Serial Number	88822744
Registration Number	6209351
Mark Literal Elements	REBLOZYL
Mark Drawing Type	-
Mark Type	TRADEMARK
Standard Character Claim	No
Register	PRINCIPAL
Current Location	NEW APPLICATION PROCESSING 2020-03-09
Basis	1(a) 44(d)
Class Status	ACTIVE
Primary US Classes	006: Chemicals and Chemical Compositions 018: Medicines and Pharmaceutical Preparations 044: Dental, Medical and Surgical Appliances 046: Foods and Ingredients of Foods 051: Cosmetics and Toilet Preparations 052: Detergents and Soaps
Primary International Class	005 - Primary Class (Pharmaceuticals) Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
Filed Use	Yes
Current Use	Yes
Intent To Use	No
Filed ITU	No
44D Filed	Yes
44E Current	No
66A Current	No
Current Basis	No
No Basis	No
Attorney Name	Camille M. Miller
Attorney Docket Number	CELG-

Timeline

IC 005. US 006 018 044 046 051 052. G & S: Pharmaceutical preparations for use in the treatment of anemia, beta thalassemia, blood disease and cancer. FIRST USE: 20191108. FIRST USE IN COMMERCE: 20191108